Asphyxia due to extrinsic tracheal compression by nonresectable tumour in the mediastinum is a particularly distressing problem, hitherto not amenable to relief by surgical means. Tracheostomy may be inappropriate, either because the tube falls short of the area of compression or because the segment of trachea at the tracheostomy site is affected by the pathological process; and endotracheal intubation is unacceptable in a spontaneously breathing and fully conscious patient. Radiotherapy is logistically difficult in patients undergoing positive-pressure ventilation and for those who are on the verge of critical major airways obstruction, and it may initially exacerbate dyspnoea by causing oedema and swelling of the tumour and surrounding tissues.
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In 1082 Westabyl described a silastic tracheobronchial stent for intubation of the diseased or injured supracarinal trachea and main bronchi (fig 1) . This is usually inserted via a tracheostomy and it has a tracheostomy side limb, which when occluded allows the patient to breath normally through the cords. We report the use of the stent without tracheostomy in a patient with a highly vascular thyroid tumour with intrathoracic extension, in whom conventional tracheostomy was impossible. We describe the method of insertion and discuss the therapeutic applications of this device. The stent has proved to be a safe and highly effective means of maintaining an airway even with very severe tracheal tumours, which might be expected to compress the pliable silicone rubber cylinder. Its presence in the trachea is well tolerated since the cough reflex disappears and the tendency to produce secretions subsides over 24-48 hours. The patient breathes normally through the larynx and when it is used without the side arm is unaware of its presence. Presumably the fact that inspired air is humidified by the upper respiratory tract accounts for the absence of secretions and crusting that occur with conventional endotracheal and tracheostomy tubes. The possibility of inserting the stent through the vocal cords without tracheostomy extends the scope of the device to include patients in whom tracheostomy through malignant tissue is inadvisable and provides a considerably more acceptable approach than anterior mediastinal tracheostomy.8 Most patients with endotracheal disease, however, are better served by the conventional stent, as the tracheostomy limb provides direct access for aspiration of secretions and serves as a fixed point to prevent dislocation of the bifurcation into the trachea. 
